Wayne Jonas, MD, executive director of Samueli Integrative Health Programs at H&S Ventures, discusses what new therapies are emerging in the world of pain management.
Transcript:
Are there any newer therapies for pain on the horizon that you are keeping an eye on?
Well, there's a number of them and the evidence is growing more and more for these. For those that are interested in, in kind of keeping up with what is reaching the level of sufficient evidence to consider for your own practice. I would urge you to look at the VA's Whole Health website, where they have a list of currently recommended approaches for chronic illness many of which are for chronic pain.
[Some] CME [continuing medical education] courses list current approaches that now have sufficient evidence to consider for everybody to put into these areas.
I know there are also increasing approaches to chronic pain with new drugs, for example, ketamine. But ketamine has great addictive potential and it can be used only cautiously in certain types of patients, chronic regional pain syndrome, for example, and some types of neuropathy. It needs to be used carefully. Most of the time has to be given [intravenous] in the office.
So, there these are new therapies that are of interest, but they need to be used appropriately based on good evidence and integrated with the leading components for chronic pain management that impact patients in the long run, which are the behavior, lifestyle, and nonpharmacological approaches.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More